

Rosalba Miceli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7638142/publications.pdf>

Version: 2024-02-01

242
papers

15,231
citations

19655
61
h-index

19747
117
g-index

247
all docs

247
docs citations

247
times ranked

16297
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. <i>Haematologica</i> , 2022, 107, 1153-1162.	3.5	15
2	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISGâ€STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	4.1	46
3	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 3274-3286.	1.5	5
4	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1723-1729.	1.0	10
5	Sarcuator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 4376-4385.	1.5	12
6	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	1.1	5
7	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , 2021, 107, 150-159.	1.1	8
8	Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters. <i>Oncology</i> , 2021, 99, 84-95.	1.9	5
9	A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 3904-3916.	1.5	14
10	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 Years. <i>Annals of Surgical Oncology</i> , 2021, 28, 1700-1709.	1.5	38
11	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4706-4717.	1.5	16
12	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 261-268.	3.1	8
13	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	1.5	19
14	Severe COVID-19 in Hospitalized Carriers of Single CFTR Pathogenic Variants. <i>Journal of Personalized Medicine</i> , 2021, 11, 558.	2.5	16
15	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. <i>European Journal of Cancer</i> , 2021, 157, 291-300.	2.8	11
16	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	1.5	26
17	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020, 130, 857-865.	2.0	25
18	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020, 106, 39-46.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Reply to E. HindiÃ©. Journal of Clinical Oncology, 2020, 38, 3238-3240.	1.6	3
20	Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. Frontiers in Oncology, 2020, 10, 1223.	2.8	2
21	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. Cancer, 2020, 126, 4917-4925.	4.1	21
22	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. European Journal of Cancer, 2020, 135, 62-65.	2.8	32
23	Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of Clinical Oncology, 2020, 38, 1591-1601.	1.6	50
24	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncology, The, 2020, 21, 947-956.	10.7	166
25	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist, 2020, 25, e460-e468.	3.7	29
26	Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1327-1336.	4.9	3
27	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. Dysphagia, 2019, 34, 52-62.	1.8	9
28	PO-160 Tumor and retropharyngeal nodal GTVs prognostic role in unresectable non-glandular sinonasal cancers. Radiotherapy and Oncology, 2019, 132, 85.	0.6	0
29	Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. Annals of Surgical Oncology, 2019, 26, 3535-3541.	1.5	10
30	Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AROâ€”Head and Neck working group. Head and Neck, 2019, 41, 3684-3692.	2.0	17
31	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1268.	7.1	70
32	OC-0070 Radiation Therapy for Retroperitoneal Liposarcoma â€” A report from TARPSWG. Radiotherapy and Oncology, 2019, 133, S32.	0.6	0
33	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	1.6	293
34	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	5.4	38
35	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. Pharmacogenomics Journal, 2019, 19, 465-472.	2.0	16
36	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. Journal of Pathology: Clinical Research, 2019, 5, 217-226.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	1.9	26
38	Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 547-556.	1.6	22
39	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	7.0	80
40	Prevalence of Fatigue in Head and Neck Cancer Survivors. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2019, 128, 413-419.	1.1	30
41	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	7.1	42
42	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	4.1	71
43	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2019, 41, 1895-1902.	2.0	10
44	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 1047-1051.	7.2	27
45	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in <i>MCMT</i> methylated, <i>RAS</i> mutated metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3509-3509.	1.6	1
46	Extracellular matrix proteins as diagnostic markers of breast carcinoma. <i>Journal of Cellular Physiology</i> , 2018, 233, 6280-6290.	4.1	49
47	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1217-1221.	0.8	9
48	Prognostic models for RPS patients”Attempting to predict patient outcomes. <i>Journal of Surgical Oncology</i> , 2018, 117, 69-78.	1.7	16
49	Prognostic role of PIK3CA and TP53 in human papillomavirus”negative oropharyngeal cancers. <i>Tumori</i> , 2018, 104, 213-220.	1.1	4
50	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	3.1	18
51	Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 1203-1215.	0.8	2
52	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	4.2	142
53	Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy. <i>Annals of Oncology</i> , 2018, 29, viii311-viii312.	1.2	0
54	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. <i>Head and Neck</i> , 2018, 40, 2648-2656.	2.0	7

#	ARTICLE	IF	CITATIONS
55	In Reply to Fakhry etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 102, 670-671.	0.8	1
56	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. European Journal of Cancer, 2018, 105, 19-27.	2.8	56
57	Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. BMC Cancer, 2018, 18, 899.	2.6	45
58	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist, 2018, 23, 1178-1187.	3.7	46
59	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. European Journal of Cancer, 2018, 97, 7-15.	2.8	34
60	PV-0432: Impact of re-irradiation volume and dose on the survival of recurrent HN cancer: an AIRO study. Radiotherapy and Oncology, 2018, 127, S228-S229.	0.6	0
61	MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner. Journal of Hematology and Oncology, 2018, 11, 45.	17.0	23
62	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	1.9	11
63	A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial.. Journal of Clinical Oncology, 2018, 36, 4502-4502.	1.6	7
64	Peritoneal Surface Oncology Group International (PSOGI) multicenter study on nomograms to predict overall survival in diffuse malignant peritoneal mesothelioma.. Journal of Clinical Oncology, 2018, 36, e15701-e15701.	1.6	0
65	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics Journal, 2017, 17, 331-336.	2.0	10
66	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 60-65.	1.3	4
67	Postâ€relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transâ€Atlantic RPS Working Group. Cancer, 2017, 123, 1971-1978.	4.1	104
68	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncology, 2017, 69, 33-37.	1.5	16
69	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clinical Genitourinary Cancer, 2017, 15, 509-512.e9.	1.9	1
70	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2017, 23, 1102-1109.	2.0	9
71	Soft tissue sarcoma nomograms and their incorporation into practice. Cancer, 2017, 123, 2802-2820.	4.1	105
72	Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research, 2017, 62, 91-97.	0.8	16

#	ARTICLE	IF	CITATIONS
73	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017, 28, 2820-2826.	1.2	66
74	PD-034: Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 20.	0.6	0
75	Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2012-2020.	1.0	20
76	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	1.2	43
77	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	1.9	27
78	First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial. <i>Annals of Oncology</i> , 2017, 28, v629.	1.2	1
79	Predicting response to chemotherapy in gastric cancer patients randomized to docetaxel: A reevaluation of the ITACA-S trial. <i>Annals of Oncology</i> , 2017, 28, v41.	1.2	0
80	A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, vi68.	1.2	0
81	Predictive factors in GEP-NEN: The integrated role of Ki67, beta-catenin and morphology. <i>Annals of Oncology</i> , 2017, 28, v152-v153.	1.2	0
82	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9543-9543.	1.6	5
83	Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 59-59.	1.6	2
84	Sarcoma nomograms: a light over the darkness. <i>Oncoscience</i> , 2017, 4, 15-16.	2.2	6
85	Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 64-64.	1.6	0
86	Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4068-4068.	1.6	0
87	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). <i>Annals of Surgery</i> , 2016, 263, 1002-1009.	4.2	392
88	Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 64, 107-112.	2.8	60
89	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	4.1	77
90	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	4.7	151

#	ARTICLE	IF	CITATIONS
91	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , 2016, 17, 671-680.	10.7	318
92	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. <i>Neuro-Oncology</i> , 2016, 18, 1451-1460.	1.2	108
93	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	1.9	12
94	Extracellular matrix proteins derived from the tumor microenvironment as circulating breast cancer diagnostic markers. <i>European Journal of Cancer</i> , 2016, 61, S42.	2.8	0
95	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	1.5	136
96	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 959-966.	0.8	48
97	Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting. <i>Annals of Oncology</i> , 2016, 27, vi342.	1.2	0
98	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 384-390.	2.4	7
99	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 49-61.	1.2	108
100	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	1.9	6
101	Osteopontin, E-cadherin, and β -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	5.3	37
102	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11045-11045.	1.6	0
103	Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6022-6022.	1.6	0
104	Androgen receptor (AR) immunohistochemical (IHC) expression in muscle invasive (miUC) or metastatic urothelial carcinoma (mUC): Evaluating a potential target for treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16025-e16025.	1.6	0
105	2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis. <i>European Journal of Cancer</i> , 2015, 51, S578.	2.8	3
106	Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. <i>Journal of Breath Research</i> , 2015, 9, 031001.	3.0	25
107	3404 External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS). <i>European Journal of Cancer</i> , 2015, 51, S689-S690.	2.8	0
108	Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. <i>BMC Bioinformatics</i> , 2015, 16, 388.	2.6	16

#	ARTICLE	IF	CITATIONS
109	Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. British Journal of Surgery, 2015, 102, 1079-1087.	0.3	43
110	KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naïve Localized GIST. American Journal of Surgical Pathology, 2015, 39, 922-930.	3.7	63
111	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. American Journal of Surgical Pathology, 2015, 39, 383-393.	3.7	101
112	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Medical Oncology, 2015, 32, 182.	2.5	22
113	416 Variant Alleles in Factor V Leiden (FVL), Prothrombin, Plasminogen Activator Inhibitor-1 (PAI-1) or Methylenetetrahydrofolate Reductase (MTHFR) and risk of thromboembolic events (TEE) in metastatic colorectal cancer (mCRC) patients. European Journal of Cancer, 2015, 51, S83-S84.	2.8	0
114	Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. European Journal of Cancer, 2015, 51, 186-192.	2.8	133
115	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. Annals of Surgical Oncology, 2015, 22, 1447-1454.	1.5	152
116	Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM+ Lung Cancer—Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. Cancer Research, 2015, 75, 3636-3649.	0.9	83
117	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiotherapy and Oncology, 2015, 117, 315-321.	0.6	28
118	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study.. Journal of Clinical Oncology, 2015, 33, 4535-4535.	1.6	0
119	Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy (Italian Intergroup Adjuvant Chemotherapy of Adenocarcinoma of the Stomach-ITACA-S Trial).. Journal of Clinical Oncology, 2015, 33, e15016-e15016.	1.6	0
120	Postoperative morbidity and mortality in a large series of primary retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the Transatlantic RPS Working Group.. Journal of Clinical Oncology, 2015, 33, 10557-10557.	1.6	0
121	Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis.. Journal of Clinical Oncology, 2015, 33, e15527-e15527.	1.6	0
122	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. PLoS ONE, 2014, 9, e92147.	2.5	18
123	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. Cancers, 2014, 6, 1753-1768.	3.7	14
124	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. Clinical Genitourinary Cancer, 2014, 12, 196-202.e1.	1.9	3
125	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. Journal of Neuro-Oncology, 2014, 118, 305-312.	2.9	61
126	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia, 2014, 28, 1885-1891.	7.2	83

#	ARTICLE	IF	CITATIONS
127	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485.	1.6	103
128	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014, 25, 694-699.	1.2	33
129	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	1.9	24
130	Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib â€“ Analysis of prognostic factors (EORTC-STBSG collaborative study). <i>European Journal of Surgical Oncology</i> , 2014, 40, 412-419.	1.0	125
131	Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemorefractory germ cell tumors (GCT): Long-term efficacy and safety outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4561-4561.	1.6	2
132	Analysis of the contemporary use of high-dose chemotherapy (HDCT) in germ cell tumors (GCT) in Europe: Early findings of an ongoing EBMT-sponsored study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15536-e15536.	1.6	1
133	Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. <i>World Journal of Gastroenterology</i> , 2014, 20, 4516.	3.3	30
134	Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 341-341.	1.6	0
135	Nomograms to predict prognosis in pseudomyxoma peritonei: A Peritoneal Surface Oncology Group International (PSOGI) multicenter study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4033-4033.	1.6	0
136	Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10020-10020.	1.6	1
137	Abstract 2852: SNAI2 expression by cancer-associated fibroblasts is a negative prognostic factor in non-small cell lung cancer. , 2014, , .		0
138	Histological variants of medulloblastoma are the most powerful clinical prognostic indicators. <i>Pediatric Blood and Cancer</i> , 2013, 60, 210-216.	1.5	38
139	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013, 49, 413-419.	1.5	39
140	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.4	36
141	Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. <i>Annals of Oncology</i> , 2013, 24, 2181-2189.	1.2	63
142	Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. <i>Annals of Oncology</i> , 2013, 24, 2967-2971.	1.2	22
143	Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. <i>Journal of Clinical Oncology</i> , 2013, 31, 1649-1655.	1.6	268
144	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	4.1	162

#	ARTICLE	IF	CITATIONS
145	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. International Journal of Biological Markers, 2013, 28, 24-31.	1.8	0
146	High pathologic response rate of hepatic colorectal cancer metastases (HCRM) following neoadjuvant bevacizumab (Bev)-based treatment (tx).. Journal of Clinical Oncology, 2013, 31, 529-529.	1.6	1
147	Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naïve metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial.. Journal of Clinical Oncology, 2013, 31, 356-356.	1.6	3
148	Abstract B33: Osteopontin expression is an independent poor prognostic marker in gastric cancer radically resected. Preliminary report of translational study of ITACA-S (Intergroup Trial of Adjuvant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		
149	Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro-Oncology, 2012, 14, 1346-1356.	1.2	42
150	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Annals of Oncology, 2012, 23, 1067-1073.	1.2	180
151	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. Journal of Clinical Oncology, 2012, 30, 850-856.	1.6	156
152	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Annals of Oncology, 2012, 23, 1832-1837.	1.2	97
153	Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study. Annals of Surgical Oncology, 2012, 19, 3361-3367.	1.5	58
154	Leiomyosarcoma and sarcoma with myogenic differentiation. Cancer, 2012, 118, 5349-5357.	4.1	3
155	Anterior craniofacial resection for malignant paranasal tumors: A monoinstitutional experience of 366 cases. Head and Neck, 2012, 34, 78-87.	2.0	35
156	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. Blood, 2012, 120, 1984-1984.	1.4	1
157	Is <i>CTNNB1</i> mutational analysis predictive for progression in patients with sporadic desmoid tumors primarily observed?. Journal of Clinical Oncology, 2012, 30, 10016-10016.	1.6	0
158	Importance of early nutritional screening in patients with gastric cancer. British Journal of Nutrition, 2011, 106, 1773-1778.	2.3	59
159	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. European Journal of Cancer, 2011, 47, 724-731.	2.8	123
160	Natural History of Imatinib-naïve GISTs. American Journal of Surgical Pathology, 2011, 35, 1646-1656.	3.7	116
161	Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. British Journal of Cancer, 2011, 104, 1256-1261.	6.4	66
162	Reply to Ilker Akyol, Hasan Soydan, and Ferhat Atesâ€™ Letter to the Editor re: Nicola Nicolai, Rosalba Miceli, Andrea Necchi, et al. Retroperitoneal Lymph Node Dissection With No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. Eur Urol 2010;58:912â€™8. European Urology, 2011, 59, e21-e22.	1.9	1

#	ARTICLE	IF	CITATIONS
163	Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up. <i>Annals of Surgical Oncology</i> , 2011, 18, 125-133.	1.5	141
164	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 720-725.	1.5	199
165	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	2.4	471
166	Myeloablative doses of yttrium-90-labeled anti-CD20 monoclonal antibody rituximab and the risk of secondary myelodysplasia/acute myelogenous leukemia. <i>Cancer</i> , 2011, 117, 5074-5084.	4.1	23
167	Survival Prediction for Terminally Ill Cancer Patients: Revision of the Palliative Prognostic Score with Incorporation of Delirium. <i>Oncologist</i> , 2011, 16, 1793-1799.	3.7	93
168	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	1.2	42
169	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011, 22, 2495-2500.	1.2	31
170	Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers (OPCs).. <i>Journal of Clinical Oncology</i> , 2011, 29, 5573-5573.	1.6	1
171	Breast change perception in women after smoking cessation. A pilot study. <i>Tumori</i> , 2011, 97, 672-5.	1.1	0
172	The symptom interval in children and adolescents with soft tissue sarcomas. <i>Cancer</i> , 2010, 116, 177-183.	4.1	66
173	Pure Desmoplastic Melanoma. <i>Annals of Surgery</i> , 2010, 252, 1052-1057.	4.2	49
174	Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control. <i>Annals of Surgical Oncology</i> , 2010, 17, 1507-1514.	1.5	257
175	Retroperitoneal Lymph Node Dissection with No Adjuvant Chemotherapy in Clinical Stage I Nonseminomatous Germ Cell Tumours: Long-Term Outcome and Analysis of Risk Factors of Recurrence. <i>European Urology</i> , 2010, 58, 912-918.	1.9	47
176	Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	4.1	93
177	Pretransplantation [¹⁸ F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. <i>Cancer</i> , 2010, 116, 5001-5011.	4.1	36
178	Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1322-1328.	1.6	58
179	Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 4589-4589.	1.6	4
180	Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size. <i>Journal of Clinical Oncology</i> , 2009, 27, 371-376.	1.6	55

#	ARTICLE	IF	CITATIONS
181	Distal clearance margin of 1 cm or less: a safe distance in lower rectum cancer surgery. International Journal of Colorectal Disease, 2009, 24, 317-322.	2.2	45
182	Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: A validation analysis. Lung Cancer, 2009, 66, 270-271.	2.0	7
183	Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers, 2009, 14, 130-136.	1.9	29
184	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology, The, 2009, 10, 35-43.	10.7	1,920
185	Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers. Journal of Thoracic Oncology, 2009, 4, 1352-1356.	1.1	30
186	Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen. Cancer, 2008, 112, 481-488.	4.1	44
187	The prognostic impact of dedifferentiation in retroperitoneal liposarcoma. Cancer, 2008, 113, 1657-1665.	4.1	81
188	RISK OF DISTANT METASTASIS FOLLOWING RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND) ALONE IN CLINICAL STAGE I (CS I) NON-SEMINOMATOUS GERM CELL TESTICULAR TUMOURS (NSGCTTs). Journal of Urology, 2008, 179, 176-176.	0.4	0
189	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia and Lymphoma, 2008, 49, 2156-2162.	1.3	143
190	Lymph Node Metastases in Malignant Tumors of the Paranasal Sinuses. JAMA Otolaryngology, 2008, 134, 170.	1.2	139
191	Lung Cancer Stage is an Independent Risk Factor for Surgical Mortality. Tumori, 2008, 94, 362-369.	1.1	6
192	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 2008, 112, 3303-3303.	1.4	26
193	Atrial fibrillation after non-cardiac surgery: P-wave characteristics and Holter monitoring in risk assessment†. European Journal of Cardio-thoracic Surgery, 2007, 31, 812-816.	1.4	20
194	Evaluation of <i>LRRK2</i> G2019S penetrance. Neurology, 2007, 68, 1141-1143.	1.1	141
195	Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. European Journal of Cancer, 2007, 43, 2691-2697.	2.8	43
196	Short-term effects of pamidronate on bone turnover: Can bone markers be considered predictive of the analgesic response?. Oncology Reports, 2007, 17, 1533-40.	2.6	6
197	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia, 2007, 21, 2316-2323.	7.2	142
198	Estimation of predictive accuracy in survival analysis using R and S-PLUS. Computer Methods and Programs in Biomedicine, 2007, 87, 132-137.	4.7	21

#	ARTICLE	IF	CITATIONS
199	Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure. <i>Annals of Surgical Oncology</i> , 2007, 14, 1583-1590.	1.5	70
200	Prognostic Value of Positron Emission Tomography (PET) Scan in Patients with Relapsed Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Receiving Salvage Chemotherapy Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 3039-3039.	1.4	3
201	Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. <i>Cancer Research</i> , 2006, 66, 6219-6224.	0.9	43
202	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2006, 13, 110-117.	1.5	141
203	Pathological features as predictors of recurrence after radical resection of gastric cancer. <i>British Journal of Surgery</i> , 2006, 93, 205-209.	0.3	45
204	Malignant peripheral nerve sheath tumors. <i>Cancer</i> , 2006, 107, 1065-1074.	4.1	358
205	Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1065-1071.	1.2	187
206	Extremity soft tissue sarcoma: The need for a differential surgical approach to primary tumor and local recurrence?. <i>Journal of Clinical Oncology</i> , 2006, 24, 9565-9565.	1.6	0
207	Which classification for ethmoid malignant tumors involving the anterior skull base?. <i>Head and Neck</i> , 2005, 27, 224-231.	2.0	19
208	Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. <i>Cancer</i> , 2005, 103, 402-408.	4.1	182
209	A Modified Prognostic Score for Patients with Curatively Resected Gastric Cancer. <i>Tumori</i> , 2005, 91, 221-226.	1.1	5
210	Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. <i>Annals of Oncology</i> , 2005, 16, 1449-1457.	1.2	92
211	Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate. <i>Journal of Clinical Oncology</i> , 2005, 23, 7669-7675.	1.6	196
212	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2005, 23, 96-104.	1.6	248
213	A modified prognostic score for patients with curatively resected gastric cancer. <i>Tumori</i> , 2005, 91, 221-6.	1.1	5
214	Revising a Prognostic Index Developed for Classification Purposes: An Application to Gastric Cancer Data. <i>Journal of Applied Statistics</i> , 2004, 31, 817-830.	1.3	9
215	A Simple Model for Predicting Nodal Metastasis in Patients With Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors Undergoing Retroperitoneal Lymph Node Dissection Only. <i>Journal of Urology</i> , 2004, 171, 172-176.	0.4	69
216	Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. <i>Maturitas</i> , 2004, 47, 11-20.	2.4	58

#	ARTICLE	IF	CITATIONS
217	Evaluation of Reactive oxygen Metabolites in Frozen Serum Samples. Effect of Storage and Repeated Thawing. International Journal of Biological Markers, 2004, 19, 250-253.	1.8	23
218	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. Annals of Surgery, 2004, 240, 900-909.	4.2	452
219	Evaluation of reactive oxygen metabolites in frozen serum samples. Effect of storage and repeated thawing. International Journal of Biological Markers, 2004, 19, 250-253.	1.8	16
220	Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?. Cancer, 2003, 97, 1156-1163.	4.1	56
221	Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. British Journal of Surgery, 2003, 86, 84-87.	0.3	168
222	Lymphadenectomy in gastric cancer: prognostic role and therapeutic implications. European Journal of Surgical Oncology, 2002, 28, 406-412.	1.0	53
223	c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients. Breast, 2002, 11, 286-294.	2.2	0
224	Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. International Journal of Biological Markers, 2002, 17, 253-258.	1.8	7
225	Perioperative Total Parenteral Nutrition in Malnourished, Gastrointestinal Cancer Patients: A Randomized, Clinical Trial. Journal of Parenteral and Enteral Nutrition, 2000, 24, 7-14.	2.6	226
226	The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. Journal of Steroid Biochemistry and Molecular Biology, 2000, 75, 65-73.	2.5	7
227	Early Gastric Cancer: Unrecognized Indicator of Multiple Malignancies. World Journal of Surgery, 2000, 24, 583-587.	1.6	10
228	Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 Serum Levels as Prognostic Indicators in Resected Non-Small Cell Lung Cancer. International Journal of Biological Markers, 1999, 14, 92-98.	1.8	9
229	Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer. Journal of the National Cancer Institute, 1999, 91, 1847-1856.	6.3	375
230	Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of "cures"™. Breast Cancer Research and Treatment, 1999, 53, 209-215.	2.5	39
231	Subtotal Versus Total Gastrectomy for Gastric Cancer. Annals of Surgery, 1999, 230, 170.	4.2	375
232	Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?. European Journal of Cancer, 1998, 34, 825-830.	2.8	46
233	Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1349-1355.	6.4	20
234	The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. Journal of Steroid Biochemistry and Molecular Biology, 1997, 63, 261-267.	2.5	33

#	ARTICLE	IF	CITATIONS
235	Impact of Distal Clearance Margin on Oncologic Outcome after Restorative Resection of the Rectum. Tumori, 1997, 83, 907-911.	1.1	9
236	Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale, Design, Methodology, Organization, Data Management, Statistics and Accrual. Tumori, 1997, 83, 884-894.	1.1	32
237	Insular Carcinoma. American Journal of Surgical Pathology, 1997, 21, 1466-1473.	3.7	109
238	Total Versus Subtotal Gastrectomy. Annals of Surgery, 1997, 226, 613-620.	4.2	165
239	Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori, 1997, 83, 884-94.	1.1	14
240	Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Research and Treatment, 1996, 41, 177-185.	2.5	233
241	Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. Breast Cancer Research and Treatment, 1995, 34, 237-244.	2.5	18
242	Covidâ€19 outbreak in Lombardy: impact on reducing solid cancer diagnoses in 2020. International Journal of Cancer, 0, , .	5.1	5